1. Home
  2. TNGX vs BNED Comparison

TNGX vs BNED Comparison

Compare TNGX & BNED Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • TNGX
  • BNED
  • Stock Information
  • Founded
  • TNGX 2014
  • BNED 1965
  • Country
  • TNGX United States
  • BNED United States
  • Employees
  • TNGX N/A
  • BNED N/A
  • Industry
  • TNGX Biotechnology: Pharmaceutical Preparations
  • BNED Other Specialty Stores
  • Sector
  • TNGX Health Care
  • BNED Consumer Discretionary
  • Exchange
  • TNGX Nasdaq
  • BNED Nasdaq
  • Market Cap
  • TNGX 351.2M
  • BNED 394.7M
  • IPO Year
  • TNGX N/A
  • BNED N/A
  • Fundamental
  • Price
  • TNGX $5.02
  • BNED $11.70
  • Analyst Decision
  • TNGX Strong Buy
  • BNED
  • Analyst Count
  • TNGX 6
  • BNED 0
  • Target Price
  • TNGX $12.20
  • BNED N/A
  • AVG Volume (30 Days)
  • TNGX 4.0M
  • BNED 408.5K
  • Earning Date
  • TNGX 08-06-2025
  • BNED 07-07-2025
  • Dividend Yield
  • TNGX N/A
  • BNED N/A
  • EPS Growth
  • TNGX N/A
  • BNED N/A
  • EPS
  • TNGX N/A
  • BNED N/A
  • Revenue
  • TNGX $40,990,000.00
  • BNED $1,567,800,000.00
  • Revenue This Year
  • TNGX N/A
  • BNED $2.74
  • Revenue Next Year
  • TNGX N/A
  • BNED N/A
  • P/E Ratio
  • TNGX N/A
  • BNED N/A
  • Revenue Growth
  • TNGX 10.09
  • BNED N/A
  • 52 Week Low
  • TNGX $1.03
  • BNED $6.05
  • 52 Week High
  • TNGX $12.02
  • BNED $14.41
  • Technical
  • Relative Strength Index (RSI)
  • TNGX 69.44
  • BNED 54.71
  • Support Level
  • TNGX $4.70
  • BNED $11.58
  • Resistance Level
  • TNGX $5.63
  • BNED $11.98
  • Average True Range (ATR)
  • TNGX 0.60
  • BNED 0.45
  • MACD
  • TNGX -0.01
  • BNED -0.01
  • Stochastic Oscillator
  • TNGX 65.38
  • BNED 65.19

About TNGX Tango Therapeutics Inc.

Tango Therapeutics Inc is a biotechnology company. It is dedicated to discovering novel drug targets and delivering the next generation of precision medicine for the treatment of cancer. It is engaged in the business of discovering and developing precision oncology therapies. It is currently developing two MTA-cooperative PRMT5 inhibitors; TNG462 for non-CNS cancers, including pancreatic and lung cancer, and TNG456, a next-generation, brain-penetrant PRMT5 inhibitor, for CNS cancers, including GBM. Its pipeline products are PRMT5 and CoREST.

About BNED Barnes & Noble Education Inc

Barnes & Noble Education Inc is an operator of bookstores in college and university campuses across the United States. The company is also engaged in providing digital education services. It operates in three reportable segments that include Retail offers existing and prospective clients the flexibility of physical, virtual, or custom store solutions, and wholesale is comprised of the wholesale and virtual retail fulfillment, and support operations of the MBS subsidiary, also Corporate Services represent unallocated shared-service costs which include corporate level expenses and other governance functions, including executive functions, such as accounting, legal, treasury, information technology, and human resources. It earns majority of the revenue from Retail segment.

Share on Social Networks: